Hong Kong's Lee's Pharmaceutical H1 profit jumps on higher-margin product sales

Lee's Pharmaceutical Holdings

31/08/2026 11:00

Overview
Hong Kong pharma maker's interim revenue grew 14.6% yr/yr for six months ended June 2026
Net income attributable to owners rose 41.4% yr/yr for the reporting period
Gross profit improved 24.3%, aided by higher-margin products and manufacturing efficiencies

Outlook
Company did not provide specific financial guidance for the current quarter or full year

Result Drivers
PRODUCT MIX - Revenue growth was driven by increased sales of licensed-in and higher-margin specialty products
MANUFACTURING EFFICIENCY - Improved product yields and cost reductions at production sites supported gross profit growth
OTHER INCOME - Operating subsidies and R&D service income contributed to higher other income

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
H1 Revenue
 
HK$796.60 mln
 
H1 Net Income Attributable
 
HK$95 mln
 

Analyst Coverage
The stock recently traded at 9 times the next 12-month earnings vs. a P/E of 8 three months ago

Reuters Recommended Reads
Aug 28 - China's Ocumension Therapeutics H1 revenue surges on higher ophthalmic product sales
Aug 28 - China's Zhaoke Ophthalmology H1 revenue rises
Aug 28 - China Traditional Chinese Medicine H1 revenue falls on decline across segments

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)